Launch of Single Cell Proteomics Services

Proteome Sciences PLC

02 October 2023

 

2 October 2023

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Launch of Commercial Single Cell Proteomics Services

Proteome Sciences plc is pleased to announce the launch of SysQuant® SCP, the commercial service for single cell proteomics using the power of its TMTpro™ isobaric labelling reagents. Where more traditional approaches can measure a few 10s of proteins on each cell using antibody labelling, SysQuant® SCP can identify more than 1,000 proteins in each study of 576 single cells and provides novel insights into individual cell biology and heterogeneity. Proteome Sciences is one of the first commercial providers of such studies which are expected to significantly improve the performance of drug development across multiple diseases including cancer, neurodegeneration, respiratory and cardiac health, and metabolic disorders. Whilst in its infancy, the field of single cell proteomics is expected to grow rapidly as drug developers look to integrate single cell genomic data with knowledge of protein changes. At the same time, the complexity of the process along with the need to purchase and maintain costly equipment represents a significant barrier to entry. The SysQuant® SCP pipeline generates and analyses quantitative mass spectrometry data to reveal subtle changes not only in individual cells but also within sub-populations of that same main cell type. This data will greatly improve understanding of the biological drivers of heterogeneity and evolution in the contexts of disease and response to therapy, which will offer new therapeutic and diagnostic targets for personalized medicine. Commenting on the launch of SysQuant® SCP, Dr. Ian Pike Chief Scientific Officer stated: "This is an important step for Proteome Sciences as we have adapted cutting-edge techniques developed in academia to make them available to the pharmaceutical and biotechnology industries through SysQuant® SCP. We have built a robust platform that will provide customers with transformational data enabling a deeper understanding of disease biology and how drugs are interacting with their targets. SysQuant® SCP  studies are highly complementary to our established workflows performed on larger samples and open up a new customer base needing  access to this valuable novel single cell information." Dr. Mariola Soehngen, Chief Executive Officer commented: "We are pleased to be one of the first CROs providing single cell proteomics to our customers. The launch of SysQuant® SCP is part of our growth strategy along with the opening of a US facility in San Diego. We believe that broadening our range of services and increasing capacity are essential as the wider pharmaceutical industry increasingly recognises the need to study changes in protein expression and function to further advance and accelerate the drug development process." Proteome Sciences plc
Dr. Mariola Soehngen, Chief Executive Officer Dr. Ian Pike, Chief Scientific Officer	Tel: [phone]
Richard Dennis, Chief Commercial Officer Abdelghani Omari, Chief Financial Officer
Allenby Capital Limited (Nominated Adviser & Broker)
John Depasquale / Jeremy Porter (Corporate Finance) Stefano Aquilino / Tony Quirke (Equity Sales & Corporate Broking)	Tel: [phone]

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

 

END